KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.…
KORU Medical Systems Inc (KRMD) Q3 2026 Earnings Call Highlights: Margin Expansion and New ...
KORU Medical Systems (NASDAQ: KRMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 73 employees.
The shares were at 3.190 USD on 20 November 2026, down 18.2% over 52 weeks. Its 52-week range is 2.860 USD to 6.608 USD: the price is 51.7% below the high and 11.5% above the low.
Its market capitalisation is 138.37M USD.
KORU Medical Systems reports return on equity of -15.5%, an operating margin of -1.2% and revenue up 11.2% year over year.
It holds more cash than debt, a net cash position of 3.86M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 6.125 USD is 92.0% above the current price. The next earnings report is expected on 11 March 2027.